Oppenheimer analyst Michael Wiederhorn raised the price target on Amedisys (NASDAQ: AMED) to $125.00 (from $103.00) while maintaining an Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE